The chief of staff of Hungary's Prime Minster, Gergely Gulyas, said on 14 January 2021 that Hungary has reached a deal with China National Pharmaceutical Group Corp ( Sinopharm) to buy COVID-19 vaccines developed by the company, Reuters news agency reported on Thursday.
According to Gulyas, vaccine shipments under the European Union's programme were arriving to Hungary way too slow.
Gulyas was also quoted as telling a government briefing that the second wave of the COVID-19 pandemic has peaked in Hungary and new infections have dropped but restrictions cannot be eased yet.
GC Biopharma granted CMO rights for Curevo Vaccine's shingles vaccine
TransCode acquires Polynoma and secures USD25m investment from CK Life Sciences
Wasatch BioLabs adds three Oxford Nanopore-developed research-use-only assays to service portfolio
GSK and IQVIA expand vaccine track with local data to drive targeted public health action
AstraZeneca launches online platform to expand patient access to medications
Sanofi increases Sanofi Ventures funding by USD625m to boost biotech and digital health investments
GC Biopharma submits IND application in South Korea for Phase 1 trial of COVID-19 vaccine candidate
AusperBio completes patient enrolment in two Phase II clinical trials of AHB-137